These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1206 related articles for article (PubMed ID: 526931)
1. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin. Neil GL; Kuentzel SL; McGovren JP Cancer Treat Rep; 1979; 63(11-12):1971-8. PubMed ID: 526931 [TBL] [Abstract][Full Text] [Related]
2. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia. McGovren JP Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690 [TBL] [Abstract][Full Text] [Related]
3. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)]. Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003 [TBL] [Abstract][Full Text] [Related]
4. Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture. Bhuyan BK; Blowers CL; Crampton SL; Shugars KD Cancer Res; 1981 Jan; 41(1):18-24. PubMed ID: 7448758 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors. Furusawa S; Mian AM Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967 [TBL] [Abstract][Full Text] [Related]
6. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799 [TBL] [Abstract][Full Text] [Related]
7. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Wallace RE; Murdock KC; Angier RB; Durr FE Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice. Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034 [TBL] [Abstract][Full Text] [Related]
9. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Fujimoto K; Oka T; Morimoto M Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of cis-dichlorodiammineplatinum(II). Wolpert-DeFilippes MK Cancer Treat Rep; 1979; 63(9-10):1453-8. PubMed ID: 498146 [TBL] [Abstract][Full Text] [Related]
12. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020 [TBL] [Abstract][Full Text] [Related]
13. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Houchens DP; Ovejera AA; Sheridan MA; Johnson RK; Bogden AE; Neil GL Cancer Treat Rep; 1979 Mar; 63(3):473-6. PubMed ID: 427827 [TBL] [Abstract][Full Text] [Related]
15. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice. Dawson KM Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of novel ailanthone derivatives in vitro and in vivo. Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149 [TBL] [Abstract][Full Text] [Related]
17. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261 [TBL] [Abstract][Full Text] [Related]
19. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice. Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Fujimoto S; Ogawa M Cancer Chemother Pharmacol; 1982; 8(2):157-62. PubMed ID: 7105379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]